Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders

被引:84
作者
Bach, Paxton [1 ]
Hartung, Daniel [2 ]
机构
[1] Univ British Columbia, British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada
[2] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Robertson Collaborat Life Sci Bldg, Portland, OR 97201 USA
关键词
Community pharmacy services; Opioid-related disorders; Opiate substitution treatment; Harm reduction; ALCOHOL BRIEF INTERVENTION; HARM REDUCTION SERVICES; SUBSTITUTION TREATMENT; MAINTENANCE TREATMENT; HIV PREVENTION; DRUG MISUSERS; ATTITUDES; METHADONE; BUPRENORPHINE; MEDICATION;
D O I
10.1186/s13722-019-0158-0
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and preventing overdose deaths. As one of the most accessible healthcare professionals in the US, pharmacists are well-positioned to participate in such activities. Historically, US pharmacists have had a limited role in the surveillance and treatment of substance use disorders. This narrative review explores the literature describing novel programs designed to capitalize on the role of the community pharmacist in helping to reduce opioid-related harms, as well as evaluations of existing practices already in place in the US and elsewhere around the world. Specific approaches examined include strategies to facilitate pharmacist monitoring for problematic opioid use, to increase pharmacy-based harm reduction efforts (including naloxone distribution and needle exchange programs), and to involve community pharmacists in the dispensation of opioid agonist therapy (OAT). Each of these activities present a potential means to further engage pharmacists in the identification and treatment of opioid use disorders (OUDs). Through a careful examination of these approaches, we hope that new strategies can be adopted to leverage the unique role of the community pharmacist to help reduce opioid-related harms in the US.
引用
收藏
页数:11
相关论文
共 96 条
[1]   Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose [J].
Abouk, Rahi ;
Pacula, Rosalie Liccardo ;
Powell, David .
JAMA INTERNAL MEDICINE, 2019, 179 (06) :805-811
[2]  
Aitken M.L., 2019, Medicines use and spending in the u.s.: A review of 2018 and outlook to 2023
[3]   Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use [J].
Alanis-Hirsch, Kelly ;
Croff, Raina ;
Ford, James H., II ;
Johnson, Kim ;
Chalk, Mady ;
Schmidt, Laura ;
McCarty, Dennis .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2016, 62 :68-73
[4]   Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update [J].
Andrilla, C. Holly A. ;
Moore, Tessa E. ;
Patterson, Davis G. ;
Larson, Eric H. .
JOURNAL OF RURAL HEALTH, 2019, 35 (01) :108-112
[5]  
[Anonymous], BEST PRACTICE RECO 1
[6]  
[Anonymous], 1995, FEDERAL REGULATION M
[7]  
[Anonymous], HON ETH PROF 2018
[8]  
[Anonymous], PREV CONS OP OV UND
[9]  
[Anonymous], LAWS REL RET SAL SYR
[10]  
[Anonymous], TRENDS USE METHADONE